摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

bis-(3,3,3-trichloro-propyl)-ether | 116151-83-8

中文名称
——
中文别名
——
英文名称
bis-(3,3,3-trichloro-propyl)-ether
英文别名
Bis-(3,3,3-trichlor-propyl)-aether;Trichloro-propylether;1,1,1-trichloro-3-(3,3,3-trichloropropoxy)propane
bis-(3,3,3-trichloro-propyl)-ether化学式
CAS
116151-83-8
化学式
C6H8Cl6O
mdl
——
分子量
308.847
InChiKey
CABMGLVFFBFGLF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES
    申请人:Sumino Yukihito
    公开号:US20120022251A1
    公开(公告)日:2012-01-26
    The present invention provides a pyrone derivative and a pyridone derivative, which are novel intermediates for synthesizing an anti-influenza drug, a method of producing the same, and a method of using the same.
    本发明提供了一种吡喃衍生物和一种吡啶酮衍生物,它们是合成抗流感药物的新型中间体,以及其制备方法和使用方法。
  • SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG
    申请人:Takahashi Chika
    公开号:US20130197219A1
    公开(公告)日:2013-08-01
    The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
    本发明提供了一种具有抗病毒效果的化合物,特别是对流感病毒具有生长抑制活性,该化合物的首选例子是一种具有依赖帽端核酸酶抑制活性的取代3-羟基-4-吡啶酮衍生物前药。
  • 2,2-Disubstituted 2,3-dihydro-1,4-benzodioxin derivatives having hypotensive activity
    申请人:ISTITUTO LUSO FARMACO D'ITALIA S.p.A.
    公开号:EP0367888A1
    公开(公告)日:1990-05-16
    2,2-Disubstituted 2,3-dihydro-1,4-benzodioxin de­rivatives of formula (I): and pharmaceutically acceptable salts thereof having in vitro high affinity and selectivity for α₁ receptors and in vivo good and long lasting hypotensive activity, with negligeable side-effects; processes for the preparation thereof and pharmaceutical compositions therefrom.
    公式(I)的2,2-二取代2,3-二氢-1,4-苯并二氧杂环己烷衍生物及其药学上可接受的盐具有体外对α₁受体的高亲和力和选择性以及体内良好且持久的降压活性,且副作用可忽略;其制备方法以及由此制备的药物组合物。
  • Heterocyclic compounds having inhibitory activity against hiv integrase
    申请人:Murai Hitoshi
    公开号:US20060128669A1
    公开(公告)日:2006-06-15
    A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.
    化合物的公式(I)为杂环化合物,其中B1为—C(R2)═或—N═; R1'为H等; R1和R2中的一个是—Z1-Z2-Z3-R5,其中Z1和Z3分别为单键,可选地取代的烷基等; Z2为单键,可选地取代的烷基等; R5为可选地取代的芳基,可选地取代的杂环芳基等,而R1和R2中的另一个是H; -A1-为—C(—Y)═C(—RA)—C(—R3)═C(—R4)—等,其中Y为OH等; RA为—COR7,其中R7为OH等; R3和R4中的一个是羧基等,而R1和R2中的另一个是H等,其为前药、药学上可接受的盐以及其溶剂化物,具有抗病毒活性,特别是对HIV整合酶的抑制活性,以及含有该化合物的制药组合物,特别是抗HIV药物。
  • Heterocyclic compounds having inhibitory activity against HIV integrase
    申请人:Murai Hitoshi
    公开号:US20060247212A1
    公开(公告)日:2006-11-02
    A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 1 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.
    化合物的式子为(I)的杂环化合物:其中B1为—C(R2)═或—N═;R1'为H等;R1和R2中的一个为-Z1-Z2-Z3-R5,其中Z1和Z3分别为单键,可选地取代的烷基等;Z2为单键,可选地取代的烷基等;R1为可选地取代的芳基,可选地取代的杂环芳基等,而R1和R2中的另一个为H;-A1-为—C(—Y)═C(—RA)—C(—R3)═C(—R4)—等,其中Y为OH等;RA为—COR7,其中R7为OH等;R3和R4中的一个为羧基等,而R1和R2中的另一个为H等。该化合物的前药、药学上可接受的盐和其溶剂化物具有抗病毒活性,特别是对HIV整合酶的抑制活性,以及含有该化合物的药物组合物,尤其是抗HIV药物。
查看更多